Intercept Pharmaceuticals Inc
Company Overview
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases. Their lead product is Ocaliva® (obeticholic acid), which is approved for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA).
The company focuses on developing treatments for chronic liver diseases where there are significant unmet medical needs. They are particularly active in research related to non-alcoholic steatohepatitis (NASH) and other liver-related conditions.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2023 | $88.79m | $95.21m | - | $1.8m | 0.00% | 1.89% |
| June 30, 2023 | $83.72m | $93.65m | - | $2.81m | 0.00% | 3.00% |
| March 31, 2023 | $67.96m | $102.65m | - | $2.81m | 0.00% | 2.74% |
Company Impact
Help us evaluate Intercept Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.